Protagonist Therapeutics (PTGX) Tops Q4 EPS by 58c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of $0.44, $0.58 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $60 million versus the consensus estimate of $40 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Acuity Brands (AYI) Tops Q3 EPS by 15c
• Rheinmetall AG (RHM:GR) (RNMBY) PT Lowered to EUR1,750 at Morgan Stanley